Literature DB >> 14521810

The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

Frederick B Ruymann1.   

Abstract

The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn, Dr. Harold Mauer and colleagues developed a more robust VAC as well as three similar drug regimens with hematopoietic growth factor support, which, in the context of surgery with or without radiotherapy, achieved a 3-year failure-free survival rate of 83% (IRS-IV) in nonmetastatic embryonal rhabdomyosarcoma. This review documents the development of VAC and some of the new directions currently being pursued by the Children's Oncology Group Soft Tissue Committee.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14521810     DOI： 10.1007/s11912-003-0012-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  22 in total

1.  Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

Authors:  J S Miser; T J Kinsella; T J Triche; M Tsokos; P Jarosinski; R Forquer; R Wesley; I Magrath
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

2.  Ifosfamide: should the honeymoon be over?

Authors:  B A Kamen; E Frenkel; O M Colvin
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

3.  Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.

Authors:  A S Pappo; E Lyden; J Breneman; E Wiener; L Teot; J Meza; W Crist; T Vietti
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

Review 4.  Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.

Authors:  C B Pratt
Journal:  Semin Oncol       Date:  1996-06       Impact factor: 4.929

5.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

6.  The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.

Authors:  J Treuner; J Suder; M Keim; P Kaatsch; D Niethammer
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

7.  Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas.

Authors:  J Treuner; E Koscielniak; M Keim
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  The Intergroup Rhabdomyosarcoma Study-II.

Authors:  H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

10.  No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.

Authors:  O Oberlin; J L Habrand; J M Zucker; M Brunat-Mentigny; M J Terrier-Lacombe; J Dubousset; J C Gentet; C Schmitt; D Ponvert; C Carrié
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544
View more
  5 in total

Review 1.  Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.

Authors:  Masato Aoki; Hisamitsu Takaya; Tomoyuki Otani; Hidekatsu Nakai; Kosuke Murakami; Noriomi Matsumura
Journal:  Int Cancer Conf J       Date:  2022-08-08

2.  Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.

Authors:  Gabriela Schneider; Ewa Bryndza; Ahmed Abdel-Latif; Janina Ratajczak; Magdalena Maj; Maciej Tarnowski; Yuri M Klyachkin; Peter Houghton; Andrew J Morris; Axel Vater; Sven Klussmann; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2013-04-24       Impact factor: 5.852

Review 3.  Current management of pediatric soft tissue sarcomas.

Authors:  Surasak Sangkhathat
Journal:  World J Clin Pediatr       Date:  2015-11-08

4.  Feasibility of chemosensitivity testing in soft tissue sarcomas.

Authors:  Marcus Lehnhardt; Thomas Muehlberger; Cornelius Kuhnen; Daniel Brett; Hans U Steinau; Hamid Joneidi Jafari; Lars Steinstraesser; Oliver Müller; Heinz H Homann
Journal:  World J Surg Oncol       Date:  2005-04-18       Impact factor: 2.754

5.  Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report.

Authors:  Tao Han; Jianjun Chen; Yuting Luan; Xiaoxia Chen; Xiaodan Yang; Yue Zhang; Gao Li; Di Wang; Zhendong Zheng
Journal:  Onco Targets Ther       Date:  2018-08-30       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.